SENP2

Across TCGA pan-cancer cohorts, SENP2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SENP2 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SENP2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SENP2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where SENP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.298	0.707	.001	40	view →
LUAD	OS	Median	II,III,IV	1.000	0.891	.008	18	view →
LSCC	OS	Median	II,III,IV	0.850	0.639	.047	1	view →
HNSC	OS	Quartile	All	0.588	0.836	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SENP2–PDAC (OS)

Open the PDAC breakdown →